Recent Development of Zolmitriptan Formulation in Migraine Therapy: Production, Metabolism and Pharmaceutical Aspects

Title:Recent Development of Zolmitriptan Formulation in Migraine Therapy: Production, Metabolism and Pharmaceutical Aspects

Volume: 24 Issue: 3

Author(s): Farha Bano, Faris F. Aba Alkhayl, Mohammad Rashid, Mohammed Ghanim Alqethami, Mohammed Omair Alsufyani, Khadijah Oudah R Alhothali, Mohammed Japer Mohammed Hakme, Abdulrahman Mohammed Al-Jarallah, Rikeshwer Prasad Dewangan*Asif Husain*

Affiliation:

• Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110 062, India

• Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110 062, India

Keywords: Triptans, zolmitriptan, ergotamine, serotonin, prevalence, age factor, NSAID, drug efficacy, 5HT_1B/1D and migraine.

Abstract: The triptans class of pharmaceuticals, which was created to treat acute migraine, is made up of indole-containing drugs that bind to a subset (1B/1D) of 5-hydroxytryptamine receptors and are agonists of serotonin receptors. At the moment, naratriptan, eletriptan, zolmitriptan, rizatriptan, almotriptan, and frovatriptan are the seven types of triptans available on the market. Among these are the FDA-approved triptans, Zolmitriptan and Sumatriptan, which are selective serotonin (5-hydroxytryptamine) agonists. Zolmitriptan, a synthetic tryptamine derivative and a well-known member of the triptan family, is available as an orally disintegrating tablet, nasal spray, and tablet. There are melt formulations of rizatriptan and zolmitriptan available on the market that are easier to use and absorb, comparable to regular pills. Recently, the FDA approved zolmitriptan, a medication with tolerability comparable to sumatriptan. Whereas zolmitriptan is only available as an oral melt or tablet, sumatriptan is available as a nasal spray, oral preparation, or self-injectable kit. The only known antimigraine drugs that were widely utilized before the triptan period were ergotamine and dihydroergotamine. However, zolmitriptan binds to plasma proteins only 25% of the time because of significant first-pass degradation. Researchers have looked into fresh ideas for solving this issue and innovations to overcome its pharmacokinetic difficulties. This article emphasizes the role of zolmitriptan in the treatment of migraines, highlighting its pharmacological properties, production, metabolism, and structural features.

Cite this article as:

Bano Farha, Aba Alkhayl F. Faris, Rashid Mohammad, Alqethami Ghanim Mohammed, Alsufyani Omair Mohammed, Alhothali Oudah R Khadijah, Hakme Japer Mohammed Mohammed, Al-Jarallah Mohammed Abdulrahman, Dewangan Prasad Rikeshwer*, Husain Asif*, Recent Development of Zolmitriptan Formulation in Migraine Therapy: Production, Metabolism and Pharmaceutical Aspects, CNS & Neurological Disorders - Drug Targets 2025; 24 (3) . https://dx.doi.org/10.2174/0118715273306929240820071521